Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Mersana Therapeutics (MRSN – Research Report), Insulet (PODD – Research Report) and Crispr Therapeutics AG (CRSP – Research Report).
Mersana Therapeutics (MRSN)
In a report issued on May 9, Colleen M. Kusy from Robert W. Baird maintained a Hold rating on Mersana Therapeutics, with a price target of $4.00. The company’s shares closed last Monday at $2.62.
According to TipRanks.com, Kusy has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Mersana Therapeutics with a $6.00 average price target.
See the top stocks recommended by analysts >>
Insulet (PODD)
In a report issued on May 9, Mike Kratky from Leerink Partners reiterated a Buy rating on Insulet, with a price target of $240.00. The company’s shares closed last Monday at $161.02.
According to TipRanks.com, Kratky is a 4-star analyst with an average return of
Insulet has an analyst consensus of Strong Buy, with a price target consensus of $232.07, a 39.8% upside from current levels. In a report issued on May 6, Wolfe Research also upgraded the stock to Buy with a $200.00 price target.
Crispr Therapeutics AG (CRSP)
Mizuho Securities analyst Salim Syed maintained a Buy rating on Crispr Therapeutics AG on May 9 and set a price target of $99.00. The company’s shares closed last Monday at $55.65.
According to TipRanks.com, Syed ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of
Currently, the analyst consensus on Crispr Therapeutics AG is a Moderate Buy with an average price target of $77.82, implying a 49.7% upside from current levels. In a report issued on May 8, Leerink Partners also maintained a Buy rating on the stock with a $80.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on MRSN:
- Mersana Therapeutics Updates Corporate Presentation Online
- Mersana sees cash, equivalents sufficient to support operating plan into 2026
- Mersana Therapeutics reports Q1 EPS (16c), consensus (18c)
- Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
